PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Physics of atomic nuclei 2022-12, Vol.85 (9), p.1608-1612
Hauptverfasser: Tishchenko, V. K., Petriev, V. M., Vlasova, O. P., Krylov, V. V., Shegai, P. V., Ivanov, S. A., Kaprin, A. D.
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Cancer
Care and treatment
Health aspects
Medical imaging
Medical Physics and Biophysics
Medical research
Medicine, Experimental
Monoclonal antibodies
Particle and Nuclear Physics
Physics
Physics and Astronomy
Prostate cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment of prostate cancer are summarized. The advantages and disadvantages of ligands based on monoclonal antibodies and their fragments as well as small molecular PSMA inhibitors are discussed.
ISSN:1063-7788
1562-692X
DOI:10.1134/S106377882209037X